参考文献/References:
[1] SIEGEL R, MA Jiemin, ZOU Zhaohui, et al. Cancerstatistics,2014[J]. CA-A Cancer Journal for Clinicians,2014, 64(1): 9-29.
[2] LUVERO D, MILANI A, LEDERMANN J A.Treatment options in recurrent ovarian cancer:latestevidence and clinical potential[J]. TherapeuticAdvances in Medical Oncology, 2014, 6(5): 229-239.
[3] WANG Wei, LIU Mingbo, GUAN Yawei, etal. Hypoxia-responsive mir-301a and mir-301bpromote radioresistance of prostate cancer cells viadownregulating NDRG2[J]. Medical Science Monitor,2016, 22: 2126-2132.
[4] CHEN Erbao, XU Xiaojing, LIU Ruiqi, et al. Small butheavy role:MicroRNAs in hepatocellular carcinomaprogression[J].Bio Med Research International, 2018，2018(22): 1-9.
[5] RUPAIMOOLE R, SLACK F J. MicroRNA therapeutics:towards a new era for the management of cancerand other diseases[J]. Nature Reviews Drug Discovery,2017, 16(3): 203-222.
[6] LANDGRAF P, RUSU M, SHERIDAN R, et al. Amammalian microRNA expression Atlas based on smallRNA library sequencing[J]. Cell, 2007, 129(7): 1401-1414.
[7] BEREZIKOV E, VAN TETERING G, VERHEUL M,et al. Many novel mammalian microRNA candidatesidentified by extensive cloning and RAKE analysis[J].Genome Research, 2006, 16(10): 1289-1298.
[8] KIM S H, CHO K H, KIM Y N, et al. Resveratrolattenuates norepinephrine-induced ovarian cancerinvasiveness through downregulating hTERTexpression[J]. Archives of Pharmacal Research, 2016,39(2): 240-248.
[9] CHANG Yaoyin, KUO Wenhung, HUNG Juihui,et al. Deregulated microRNAs in triple-negativebreast cancer revealed by deep sequencing[J]. MolCancer,2015,14(1):36.
[10] W U X i f e n g , AJANI J A , G U J i a n , e t a l .MicroRNA expression signatures during malignantprogression from Barrett’s esophagus to esophagealadenocarcinoma[J]. Cancer Prevention Research(Philadelphia, Pa.), 2013, 6(3): 196-205.
[11] KOUTOVA L, STERBOVA M, PAZOURKOVA E, etal. The impact of standard chemotherapy on miRNAsignature in plasma in AML patients [J]. Leuk Res,2015, 39(12): 1389-1395.
[12] SYED S N, BRUNE B. MicroRNAs as emergingregulators of signaling in the tumor microenvironment[J]. Cancers, 2020, 12(4): 911.
[13] CUCCI M A, GRATTAROLA M, DIANZANI C, et al.Ailanthone increases oxidative stress in CDDP-resistantovarian and bladder cancer cells by inhibiting ofNrf2 and YAP expression through a post-translationalmechanism. [J]. Free radical Biology & Medicine,2020, 150: 125-135.
[14] MOU Huaping, GUO Ping, LI Xiaoming, et al. Nitidinechloride inhibited the expression of S phase kinaseassociatedprotein 2 in ovarian cancer cells[J]. CellCycle, 2017, 16(14):1366-1375.
[15] CAI Xiaoniao, YU Leilei, CHEN Zhen, et al. ArsenicTrioxide-induced upregulation of miR-1294 suppressestumor growth in hepatocellular carcinoma by targetingTEAD1 and PIM1[J]. Cancer Biomarkers, 2020,28(1):1-10.
[16] YIN Lei, LI Wenjia, XU Aiming, et al. SH3BGRL2inhibits growth and metastasis in clear cell renalcell carcinoma via activating hippo/TEAD1-Twist1pathway[J]. EBioMedicine, 2020, 51:102596.
[17] WANG Hongxiang, QIN Rong, MAO Jian, et al.CPEB4 regulates glioblastoma cell proliferationand predicts poor outcome of patients [J]. ClinicalNeurology and Neurosurgery, 2018, 169: 92-97.
[18] YANG Dong, LIU Kaiyuan, FAN Lin, et al. LncRNARP11-361F15.2 promotes osteosarcoma tumorigenesisby inhibiting M2-Like polarization of tumor-associatedmacrophages of CPEB4 [J]. Cancer Letters, 2020,473:33-49.
[19] GU Naibing，WANG Xinlai， DI Zhengli，et al.Silencing lncRNA FOXD2-AS1 inhibits proliferation, migration, invasion and drug resistance of drugresistantglioma cells and promotes their apoptosisvia microRNA-98-5p/CPEB4 axis [J]. Aging, 2019,11(22): 10266-10283.
相似文献/References:
[1]顾益凤,朱自力,张金业,等.利用ROC曲线选择血清HE-4对卵巢癌的最佳诊断界点[J].现代检验医学杂志,2015,30(04):141.[doi:10.3969/j.issn.1671-7414.2015.04.043]
GU Yi-feng,ZHU Zi-li,ZHANG Jin-ye,et al.Selecting the Best Cut-off Point
of Serum HE-4 in Ovarian Cancer by ROC Curve[J].Journal of Modern Laboratory Medicine,2015,30(04):141.[doi:10.3969/j.issn.1671-7414.2015.04.043]
[2]郑福利,张颖,王建.血清S100A6检测对卵巢上皮性癌的诊断价值[J].现代检验医学杂志,2015,30(05):22.[doi:10.3969/j.issn.1671-7414.2015.05.007]
ZHENG Fu-li,ZHANG Ying,WANG Jian.Study on Diagnostic Value of Detecting Serum S100A6
in the Epithelial Ovarian Carcinoma[J].Journal of Modern Laboratory Medicine,2015,30(04):22.[doi:10.3969/j.issn.1671-7414.2015.05.007]
[3]詹颉,常宁宁,李小侠,等.CEA，AFP，CA125，CA199和CA72-4联合检测在鉴别卵巢良恶性疾病中的应用价值[J].现代检验医学杂志,2015,30(05):50.[doi:10.3969/j.issn.1671-7414.2015.05.015]
ZHAN Jie,CHANG Ning-ning,LI Xiao-xia,et al.Clinical Value of Combined Detection of CEA，AFP，CA125，CA199 and
CA72-4 in the Identification of Ovarian Benign and Malignant Disease[J].Journal of Modern Laboratory Medicine,2015,30(04):50.[doi:10.3969/j.issn.1671-7414.2015.05.015]
[4]邢瑞青,吴永昌,陈慧昱,等.血清CA125,HE4及ROMA指数对卵巢癌诊断价值的临床研究[J].现代检验医学杂志,2016,31(06):37.[doi:10.3969/j.issn.1671-7414.2016.06.010]
XING Rui-qing,WU Yong-chang,CHEN Hui-yu,et al.Diagnostic Value of Serum CA125,HE4 and ROMA Index in Patients with Ovarian Cancer[J].Journal of Modern Laboratory Medicine,2016,31(04):37.[doi:10.3969/j.issn.1671-7414.2016.06.010]
[5]张 悦a,段海霞,暴 蕾a,等.microRNA-125b在葛根素诱导人卵巢癌细胞SKOV3凋亡中的作用研究[J].现代检验医学杂志,2017,32(05):13.[doi:10.3969/j.issn.1671-7414.2017.05.004]
ZHANG Yuea,DUAN Hai-xia,BAO Leia,et al.Role of MicroRNA-125b in Human Ovarian Cancer Cell
SKOV3 Induced Apoptosis by Puerarin[J].Journal of Modern Laboratory Medicine,2017,32(04):13.[doi:10.3969/j.issn.1671-7414.2017.05.004]
[6]徐金良a,杜丹丹,翟志敏,等.卵巢良恶性肿瘤患者血液NLR,LMR,RDW,PLR四项参数的变化及其临床意义[J].现代检验医学杂志,2018,33(02):16.[doi:10.3969/j.issn.1671-7414.2018.02.001]
XU Jin-lianga,DU Dan-dan,ZHAI Zhi-min,et al.Changes and Clinical Significance of Four Parameters of NLR,LMR,
RDW and PLR in Patients with Benign and Malignant Ovarian Tumors[J].Journal of Modern Laboratory Medicine,2018,33(04):16.[doi:10.3969/j.issn.1671-7414.2018.02.001]
[7]马同敏,赵志强.血清CA125,STIP1和IGF-Ⅰ联合检测对卵巢癌的早期诊断价值研究[J].现代检验医学杂志,2018,33(06):50.[doi:10.3969/j.issn.1671-7414.2018.06.013]
MA Tong-min,ZHAO Zhi-qiang.Clinical Value of Combined Detection of Serum CA125,STIP1 and IGF-I Levels in Early Diagnosis of Ovarian Cancer[J].Journal of Modern Laboratory Medicine,2018,33(04):50.[doi:10.3969/j.issn.1671-7414.2018.06.013]
[8]张善弟,荆成宝,禹 梅.血清CEA,CA125和HE4联合检测对卵巢癌的诊断价值[J].现代检验医学杂志,2018,33(06):122.[doi:10.3969/j.issn.1671-7414.2018.06.032]
ZHANG Shan-di,JING Cheng-bao,YU Mei.Clinical Value of Combined Detection of Serum CEA,CA125 and HE4 in the Diagnosis of Ovarian Cancer[J].Journal of Modern Laboratory Medicine,2018,33(04):122.[doi:10.3969/j.issn.1671-7414.2018.06.032]
[9]刘 青,邓慧敏,周林涛,等.卵巢癌患者组织中miR-135b的表达及临床意义[J].现代检验医学杂志,2019,34(02):32.[doi:10.3969/j.issn.1671-7414.2019.02.009]
LIU Qing,DENG Hui-min,ZHOU Lin-tao,et al.Expression and Clinical Significance of miR-135bin Tissues of Patients with Ovarian Cancer[J].Journal of Modern Laboratory Medicine,2019,34(04):32.[doi:10.3969/j.issn.1671-7414.2019.02.009]
[10]杨立芬,何建清,尹立新,等.人卵巢癌细胞SKOV3中壳多糖酶3样蛋白1的表达和对细胞增殖及侵袭的影响实验研究[J].现代检验医学杂志,2021,36(04):31.[doi:10.3969/j.issn.1671-7414.2021.04.007]
YANG Li-fen,HE Jian-qing,YIN Li-xin,et al.Expression of Chitinase 3-like Protein 1 in Human Ovarian Cancer Cell Skov3and Its Effect on Cell Proliferation and Invasion[J].Journal of Modern Laboratory Medicine,2021,36(04):31.[doi:10.3969/j.issn.1671-7414.2021.04.007]